AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence (AI) applications, aiming to develop an antibody to combat cancer.
This collaboration underscores the escalating trend of integrating AI technology into pharmaceutical research.
The partnership aims to utilize Absci's advanced AI technology for extensive protein analysis, primarily identifying a viable cancer treatment.
In the Financial Times Full story available on Benzinga.com